Search for a trial

The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with stiff knee gait

To determine the effect of botulinum toxin type A injections in stroke patients with stiff knee gait.

ROX CONTROL HTN Study: A Prospective, Randomized, Open-Label, Multicenter Study to Evaluate
the ROX Coupler in Patients with Resistant Hypertension

The objective of this study is to evaluate the safety and performance of the ROX Coupler in subjects with resistant hypertension.

A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of
the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and
Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal
Impairment

The primary objective of this study is to evaluate the long-term safety and tolerability of the TAK-491CLD FDC in comparison to the OLM/HCTZ FDC in hypertensive subjects with moderate renal impairment.

A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg / valsartan 320 mg in patients with essential hypertension.

The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.

SYMPATHY-NTX study Catheter-based Renal Sympathectomy for Hypertension after Kidney Transplantation - a feasibility study.

Objective: To test the efficacy and safety of percutaneous renal sympathetic denervation of the native kidneys in the treatment of uncontrolled hypertension in kidney transplant recipients.

An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension - A Long-Term Follow-Up to Protocol TDE-PH-310

To provide UT-15C for eligible subjects who participated in study protocol TDE-PH-310

An extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension

To provide continuing open-label treatment with bardoxolone methyl as part of this extended access program while collecting ongoing safety and tolerability data of bardoxolone methyl.